Health insurance plans are abandoning GLP-1s like Wegovy and Zepbound. Why?

The future of GLP-1 drugs will always depend on affordability. These drugs still cost hundreds of dollars a month if you pay cash, at which point access becomes a privilege: High-paid executives who want to lose weight may be able to afford it, but low-income workers who need drugs to significantly lose weight may not—unless their health insurance covers it.

For a while, the trend line for GLP-1 insurance coverage was positive. As of 2026, approximately two-thirds of private employer plans (which provide coverage for half of Americans) cover GLP-1 weight loss drugs to treat obesity. This summer, Medicare launched a new $50-a-month prescription plan. The United States has been battling an obesity epidemic for decades, but it looks like powerful drugs to treat obesity are finally starting to be integrated more seamlessly into the health system.

At least that’s what happened earlier this year. But now, private plans are exiting GLP-1 coverage. People are caught in a dilemma, debating whether to try to pay for these medications themselves or stop taking medications that they believe are having a real impact on their health.

This dilemma exposes one of the structural flaws in American health care. For working-age adults, your coverage depends on your job. Unfortunately, because people no longer hold the same job for decades, employers have no strong financial incentive to make investments that will benefit your long-term health—but there is a strong incentive to minimize short-term costs. This perverse rationale could force employer-sponsored health plans to stop covering a drug that, if taken over a person’s lifetime, not only helps them lose weight but ultimately reduces their risk of heart disease, kidney disease and other chronic health problems, improves their health, and saves us all money as they age.

“Employers or insurance companies making coverage decisions don’t necessarily care about whether they save Medicare money,” said Dan Sacks, a health care economist at the University of Wisconsin-Madison. “This is a classic problem with the U.S. health insurance system, and it’s certainly prominent here.”

This mismatch between what’s good for people’s health and what’s good for corporate profits has long been one of the fundamental flaws in the U.S. health system. Now, as GLP-1 drugs begin to truly alleviate America’s obesity crisis, access to these drugs is dwindling. The stakes couldn’t be higher.

Why employer-sponsored health plans suddenly dropped GLP-1 coverage

From the beginning, insurance coverage was a big issue for GLP-1 and its potential to revolutionize American health care. But recently, we seem to be turning a corner.

When I attended the Aspen Ideas: Wellness Festival over the summer, pharmaceutical representatives seemed visibly relieved that GLP-1 coverage was expanding among private insurance companies. By 2026, about two-thirds of employer-sponsored plans will cover some of these weight-management drugs, up from about 20% the year before.

“They recognize this is an investment in their workforce,” said Laura Steele, head of cardiometabolic health at Eli Lilly and Company, which makes Zepbound and Foundayo. “Yes, there are budgets and every employer has benefits designed. That’s real. This isn’t going away. But they also recognize the overall cost they experience if they don’t deal with this issue.”

But as employers and private insurers made coverage decisions for next year, they suddenly pulled back. At least 10% of employer plans that currently cover GLP-1 weight loss say they may stop covering it in 2027, and that number is likely to increase, according to a survey by the Health Business Group. A Mercer survey of large employers found that 6% have already eliminated coverage in 2026 and another 5% plan to eliminate it in 2027 or are actively considering it. A separate report from the Massachusetts Health Policy Commission found that the number of commercially insured people taking GLP-1 drugs in the state fell by 50% between 2025 and the first quarter of 2026, as private insurance began to decline.

Some of America’s biggest brands are reportedly eliminating or reducing their coverage: PepsiCo, Starbucks and Lowe’s among them. Their reason is simple: it’s too expensive. The net price of these drugs remains high—$600 or more for a 30-day supply—and the underlying demand is high (two out of every five American adults are obese).

When many people start taking expensive medications at the same time, costs to employer insurance plans will increase—and they have to figure out how to adapt. Insurance companies set premiums at the beginning of each year based on how many people are enrolled in the plan and how much health care they anticipate they will need. But if those estimates don’t match up — for example, if more people are taking the expensive GLP-1 drug than insurers expect — they have to offset those costs somehow, and raising premiums for the next year is a common solution. According to one estimate, premiums are expected to increase by 5% to 13% due to GLP-1 costs, and the burden of paying these higher premiums may fall on workers. Employers can also try to limit the use of GLP-1 drugs, such as by requiring workers to pay more for these drugs; 27% of large U.S. employers have implemented some kind of use control on GLP-1 drugs in the past year or plan to do so in the next year, according to Mercer.

They can also choose to stop covering these weight-loss drugs altogether — a route more and more people are deciding to take. The sudden reversal caught even economists like Sacks off guard.

“I’m surprised that someone would make a U-turn because I think they understand the trade-offs,” Sachs said. “My guess is that it’s more expensive than they expected: usage is higher, and more people might stick with it. That’s one of the reasons you might not want to keep offering it.”

To an employer, the short-term costs of a covered drug often outweigh the long-term benefits the drug may provide, at least from the employer’s perspective. An analysis produced by Blue Cross Blue Shield Kansas concluded that using GLP-1 for weight loss would increase average employee health costs by $7,000 in the first year and another $4,200 in the second year, primarily due to the cost of the drug itself. But at the same time, obesity-related medical events did not decrease during this period. Another study by Sacks and colleagues at Indiana University and the University of South Carolina found that GLP-1 use did not result in any cost savings over five years.

So, in the short term, these employers are arguably making an economically sound decision, but that decision may still come at the expense of their employees. “I’m totally screwed,” one person on Reddit said of Cigna’s plan to drop GLP-1 coverage for its employees. They expect a one-month supply (in cash terms) to be at least $300.

They’re not alone: ​​”I’m heartbroken,” another said, commenting on Starbucks’ decision to stop covering GLP-1 drugs. They said they suffered from an autoimmune disease that made losing weight difficult—until this new drug became available.

Where will GLP-1 coverage go from here?

How did we end up like this? Does it make good business sense for companies to make decisions that could harm employee health in the long term? This is at least partly a result of the haphazard way America insures its people.

When employer-sponsored insurance took off in the mid-20th century and eventually became the main way to cover the working-age population, people tended to stay in the same job for a long time. In theory, this is a synergy: Companies want their employees to stay productive, so it pays to invest in their long-term health through insurance benefits. Studies have found that people who stay with the same company and insurance plan tend to have better health outcomes than those who switch frequently.

But today, people are constantly changing jobs or doing odd jobs to scrape together an income. You probably don’t want to stay at your job for 10 years, and your employer doesn’t want you to either. Instead, they want to keep their costs as low as possible in the short term. This led them to cut coverage of GLP-1, even though doctors do believe people can benefit greatly from the weight loss these drugs help them achieve, and all of its potential health benefits, in the long term.

“These drugs have real health benefits,” Sachs told me. “The fact that we didn’t find reimbursement or that they were more expensive than we thought doesn’t necessarily mean we shouldn’t cover them.”

In theory, the market is supposed to solve the price problem: drug companies get a period of exclusivity on the drugs they develop, and then, once that period passes, cheaper generics enter the market. But generic semaglutide won’t be available in the U.S. until at least 2031, and for some versions, generic competitors won’t be available until the 2040s. Offering GLP-1 coverage may become a competitive advantage for employers, who can offer this benefit to attract potential workers as part of their benefits package.

But beyond that, the path to more affordable GLP-1 is not yet clear. Many people are already willing to pay cash for these drugs—and that’s likely to continue as long as people can afford to do so. But with inflation still rising steadily, these drugs may be out of reach for more and more Americans.

The government may be involved, but currently the federal government’s negotiating powers only cover Medicare, not private plans that are dropping coverage. Serious health care reform likely won’t be discussed until at least 2028, if Democrats win Congress and the White House and decide to make health care a legislative priority.

But the lesson of recent developments is that at some point, the United States may have to take a hard look at the underlying issues that created this mess in the first place. A patchwork approach to insuring people that prioritizes short-term cost cutting over people’s long-term health is not a true health care system.